High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France - Sorbonne Université Access content directly
Journal Articles Revue Neurologique Year : 2022

High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France

Nicolas Villain
  • Function : Author
  • PersonId : 1133683
CHU Pitié-Salpêtrière [AP-HP]
V Planche
Institut des Maladies Neurodégénératives [Bordeaux]
R Levy
  • Function : Author
  • PersonId : 1235202
  • IdHAL : rachel-levy
CHU Pitié-Salpêtrière [AP-HP]

Domains

Psychiatrics and mental health
Fichier principal
Vignette du fichier
Villain2022_Part2.pdf (777.57 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Nicolas VILLAIN  : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-03852664

Submitted on : Tuesday, November 15, 2022-10:08:52 AM

Last modification on : Saturday, October 7, 2023-9:36:20 PM

Long-term archiving on: Thursday, February 16, 2023-6:42:27 PM

Download

Dates and versions

hal-03852664 , version 1 (15-11-2022)

Identifiers

Cite

Nicolas Villain, V Planche, R Levy. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France. Revue Neurologique, In press, ⟨10.1016/j.neurol.2022.08.002⟩. ⟨hal-03852664⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

CNRS SORBONNE-UNIVERSITE SU-MEDECINE
29 View
52 Download

Altmetric

Share

Gmail Facebook X LinkedIn More